HUP9904173A2 - Pharmaceutical composition for treating viral diseases - Google Patents
Pharmaceutical composition for treating viral diseasesInfo
- Publication number
- HUP9904173A2 HUP9904173A2 HU9904173A HUP9904173A HUP9904173A2 HU P9904173 A2 HUP9904173 A2 HU P9904173A2 HU 9904173 A HU9904173 A HU 9904173A HU P9904173 A HUP9904173 A HU P9904173A HU P9904173 A2 HUP9904173 A2 HU P9904173A2
- Authority
- HU
- Hungary
- Prior art keywords
- phenyl
- pharmaceutical composition
- viral diseases
- treating viral
- piperazinyl
- Prior art date
Links
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000008194 pharmaceutical composition Substances 0.000 title 1
- 230000003612 virological effect Effects 0.000 title 1
- 241000725643 Respiratory syncytial virus Species 0.000 abstract 2
- HBIIDJDBPRTHCQ-UHFFFAOYSA-N 2-[2-[2-[[4-(4-chlorophenyl)phenyl]methyl]piperazin-1-yl]ethoxy]acetic acid Chemical group OC(=O)COCCN1CCNCC1CC1=CC=C(C=2C=CC(Cl)=CC=2)C=C1 HBIIDJDBPRTHCQ-UHFFFAOYSA-N 0.000 abstract 1
- JQJLYDIKADEXOP-UHFFFAOYSA-N Cl.Cl.ClC1=CC=C(C=C1)C1=CC=C(C=C1)CC1N(CCNC1)CCOCC(=O)O Chemical compound Cl.Cl.ClC1=CC=C(C=C1)C1=CC=C(C=C1)CC1N(CCNC1)CCOCC(=O)O JQJLYDIKADEXOP-UHFFFAOYSA-N 0.000 abstract 1
- 229940124056 Histamine H1 receptor antagonist Drugs 0.000 abstract 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 239000004480 active ingredient Substances 0.000 abstract 1
- 239000000938 histamine H1 antagonist Substances 0.000 abstract 1
- 230000002401 inhibitory effect Effects 0.000 abstract 1
- 210000003205 muscle Anatomy 0.000 abstract 1
- 239000000825 pharmaceutical preparation Substances 0.000 abstract 1
- 230000010076 replication Effects 0.000 abstract 1
- 235000002639 sodium chloride Nutrition 0.000 abstract 1
- 239000011780 sodium chloride Substances 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Virology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
A találmány egy RSV (respiratőry syncytial virűs) replikációjánakgátlására alkalmas gyógyszerkészítményre vőnatkőzik, amelyhatóanyagként 2-[2-[4-(4-klór-fenil)-fenil-metil]-1-piperazinil]-etőxi-ecetsavat, annak őptikailag tiszta izőmerjét vagygyógyszerészetileg elfőgadható sóját tartalmazza. A 2-[2-[4-(4-klór-fenil)-fenil-metil]-l-piperazinil]-etőxi-ecetsav-dihidrőklőridközismert hisztamin H1 receptőr antagőnista. ŕThe invention relates to a pharmaceutical preparation suitable for inhibiting the replication of RSV (respiratory syncytial virus), which as active ingredient is 2-[2-[4-(4-chloro-phenyl)-phenyl-methyl]-1-piperazinyl]-ethoxyacetic acid, its optically pure muscle water or pharmaceutical contains table salt. 2-[2-[4-(4-Chloro-phenyl)-phenyl-methyl]-1-piperazinyl]-ethoxy-acetic acid dihydrochloride is a known histamine H1 receptor antagonist. ŕ
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP96870114 | 1996-09-11 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| HUP9904173A2 true HUP9904173A2 (en) | 2000-05-28 |
| HUP9904173A3 HUP9904173A3 (en) | 2001-04-28 |
Family
ID=8226163
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HU9904173A HUP9904173A3 (en) | 1996-09-11 | 1997-09-08 | Pharmaceutical composition for treating viral diseases |
Country Status (23)
| Country | Link |
|---|---|
| US (1) | US6413970B1 (en) |
| EP (1) | EP0936909A1 (en) |
| JP (1) | JP2001500143A (en) |
| KR (1) | KR20000036025A (en) |
| CN (1) | CN1230116A (en) |
| AP (1) | AP9901474A0 (en) |
| AR (1) | AR009756A1 (en) |
| AU (1) | AU717354B2 (en) |
| BR (1) | BR9712033A (en) |
| CA (1) | CA2265542A1 (en) |
| CZ (1) | CZ83099A3 (en) |
| EA (1) | EA001262B1 (en) |
| HU (1) | HUP9904173A3 (en) |
| ID (1) | ID21369A (en) |
| IL (1) | IL128351A0 (en) |
| NO (1) | NO991164D0 (en) |
| NZ (1) | NZ334571A (en) |
| OA (1) | OA10993A (en) |
| PE (1) | PE107598A1 (en) |
| PL (1) | PL332316A1 (en) |
| TR (1) | TR199900523T2 (en) |
| WO (1) | WO1998010764A1 (en) |
| ZA (1) | ZA977874B (en) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB2324242A (en) * | 1997-04-18 | 1998-10-21 | Atindra Nath Chakrabarty | Medicaments for treating viral infections |
| CA2376785A1 (en) * | 1999-06-28 | 2001-01-04 | Janssen Pharmaceutica N.V. | Benzimidazoles and imidazopyridines as respiratory syncytial virus replication inhibitors |
| SK18942001A3 (en) | 1999-06-28 | 2002-10-08 | Janssen Pharmaceutica N. V. | Respiratory syncytial virus replication inhibitors |
| UA74787C2 (en) | 1999-06-28 | 2006-02-15 | Janssen Pharmaceutica Nv | Respiratory syncytial virus replication inhibitors |
| DE60319227T2 (en) | 2002-07-02 | 2009-05-07 | Ucb Farchim S.A. | DIARYLMETHYLPIPERAZINES AS PROPHYLACTIC OR THERAPEUTIC AGENTS AGAINST VIRAL MYOCARDITIS |
| CA2488114A1 (en) * | 2002-12-04 | 2004-06-17 | Dr. Reddy's Laboratories Limited | Polymorphic forms of dihydrochloride salts of cetirizine and processes for preparation thereof |
| KR100698400B1 (en) | 2004-04-14 | 2007-03-23 | 이은주 | Pharmaceutical composition for treating hair loss and benign prostatic hyperplasia |
| CN102988346A (en) * | 2012-11-19 | 2013-03-27 | 何晓涛 | Application of Aphanamixoid A in respiratory syncytial virus (RSV) resistant medicine |
| CN103356650A (en) * | 2013-07-04 | 2013-10-23 | 丁圣雨 | Application of Chukrasone A in preparing medicines for treating respiratory syncytial virus |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FI75816C (en) * | 1981-02-06 | 1988-08-08 | Ucb Sa | Process for the preparation of therapeutically active 2- [4- (diphenylmethyl) -1-piperazinyl] -acetic acid or its amide |
-
1997
- 1997-08-26 PE PE1997000761A patent/PE107598A1/en not_active Application Discontinuation
- 1997-09-02 ZA ZA977874A patent/ZA977874B/en unknown
- 1997-09-08 AP APAP/P/1999/001474A patent/AP9901474A0/en unknown
- 1997-09-08 EA EA199900226A patent/EA001262B1/en not_active IP Right Cessation
- 1997-09-08 WO PCT/EP1997/004859 patent/WO1998010764A1/en not_active Application Discontinuation
- 1997-09-08 IL IL12835197A patent/IL128351A0/en unknown
- 1997-09-08 PL PL97332316A patent/PL332316A1/en unknown
- 1997-09-08 TR TR1999/00523T patent/TR199900523T2/en unknown
- 1997-09-08 AU AU46213/97A patent/AU717354B2/en not_active Ceased
- 1997-09-08 US US09/254,548 patent/US6413970B1/en not_active Expired - Fee Related
- 1997-09-08 JP JP10513226A patent/JP2001500143A/en active Pending
- 1997-09-08 CZ CZ99830A patent/CZ83099A3/en unknown
- 1997-09-08 CA CA002265542A patent/CA2265542A1/en not_active Abandoned
- 1997-09-08 CN CN97197831A patent/CN1230116A/en active Pending
- 1997-09-08 NZ NZ334571A patent/NZ334571A/en unknown
- 1997-09-08 EP EP97944846A patent/EP0936909A1/en not_active Withdrawn
- 1997-09-08 BR BR9712033-2A patent/BR9712033A/en not_active Application Discontinuation
- 1997-09-08 KR KR1019997002003A patent/KR20000036025A/en not_active Application Discontinuation
- 1997-09-08 ID IDW990073A patent/ID21369A/en unknown
- 1997-09-08 HU HU9904173A patent/HUP9904173A3/en unknown
- 1997-09-11 AR ARP970104166A patent/AR009756A1/en not_active Application Discontinuation
-
1999
- 1999-03-10 NO NO991164A patent/NO991164D0/en not_active Application Discontinuation
- 1999-03-10 OA OA9900054A patent/OA10993A/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| OA10993A (en) | 2003-03-04 |
| US6413970B1 (en) | 2002-07-02 |
| TR199900523T2 (en) | 1999-05-21 |
| NZ334571A (en) | 2000-10-27 |
| PL332316A1 (en) | 1999-08-30 |
| CN1230116A (en) | 1999-09-29 |
| AU4621397A (en) | 1998-04-02 |
| NO991164L (en) | 1999-03-10 |
| CA2265542A1 (en) | 1998-03-19 |
| ZA977874B (en) | 1999-03-02 |
| IL128351A0 (en) | 2000-01-31 |
| AP9901474A0 (en) | 1999-03-31 |
| BR9712033A (en) | 2000-01-18 |
| WO1998010764A1 (en) | 1998-03-19 |
| HUP9904173A3 (en) | 2001-04-28 |
| NO991164D0 (en) | 1999-03-10 |
| ID21369A (en) | 1999-05-27 |
| CZ83099A3 (en) | 1999-06-16 |
| AR009756A1 (en) | 2000-05-03 |
| KR20000036025A (en) | 2000-06-26 |
| EA199900226A1 (en) | 1999-08-26 |
| EA001262B1 (en) | 2000-12-25 |
| JP2001500143A (en) | 2001-01-09 |
| EP0936909A1 (en) | 1999-08-25 |
| AU717354B2 (en) | 2000-03-23 |
| PE107598A1 (en) | 1999-01-29 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2395500C2 (en) | 2,4-pyrimidine diamines used in treating neoplastic diseases, inflammatory and immune disorders | |
| NZ515392A (en) | Respiratory syncytial virus replication inhibitors | |
| WO1997020823A3 (en) | 2-amino quinazoline derivatives as npy receptor antagonists | |
| ATE300941T1 (en) | PHARMACEUTICAL FORMULATION CONTAINING TOLTERODINE AND USE THEREOF | |
| BR0108378A (en) | Crystalline salt of a compound, pharmaceutical composition, process for the manufacture of said salt, and use thereof | |
| IL155919A (en) | (e) - 7 - [4 - (4 - fluorophenyl) - 6 - isopropyl - 2 - [methyl ( methylsulfonyl) amino] pyrimidin - 5 - yl] (3r, 5s) - dihydroxyhept - 6 - enoic acid, or a pharmaceutically acceptable salt thereof, for use as a medicament for the treatment of heterozygous familial hypercholesterolemia | |
| BRPI0518861B8 (en) | pharmaceutically acceptable compounds, salts or hydrates, pharmaceutical composition and use of therapeutically or prophylactically effective amount of compound or pharmaceutical composition | |
| BRPI0513565A (en) | compound or a pharmaceutically acceptable salt thereof, methods for inhibiting a protein kinase activity, and for treating a patient having a condition that is mediated by protein kinase activity, use of a compound or a pharmaceutically acceptable salt thereof, and, pharmaceutical composition | |
| NL300202I1 (en) | Nucleotide analogs. | |
| BR0101456A (en) | Combinations of corticotropin-deliberating factor antagonists and growth hormone secretagogues | |
| BRPI0409498A (en) | use of a compound, pharmaceutical formulation, compound, pharmaceutical composition, and process for preparing a compound | |
| HUP9904173A2 (en) | Pharmaceutical composition for treating viral diseases | |
| BR9912142A (en) | Substituted 6-benzyl-4-oxypyrimidines, process for their preparation and compositions containing them | |
| BR0107912A (en) | Compound, compositions, and, methods for treating or preventing cancer or neoplastic disease, method for inhibiting the development of a cancer cell or neoplastic cell, method for treating or preventing viral infection in a patient, and for inhibiting replication or infectivity of a virus | |
| BR0015540A (en) | Adenosine receptor antagonists and methods of preparing and using them | |
| BRPI0410050A (en) | method of treatment or prophylaxis of psychotic disorders, disorders of intellectual impairment or diseases or conditions in which alpha-nicotinic receptor modulation is beneficial, pharmaceutical composition, method of treatment or prophylaxis of diseases, use of a compound, compound, and , method of preparing a compound | |
| DK0560822T3 (en) | Process for the preparation of a fixed unit dose controlled release form | |
| BR0213037A (en) | Pyrimidine Derivatives | |
| ATE366107T1 (en) | USE OF SULFODEHYDROABIETIC ACID TO TREAT INFLAMMATORY BOWEL DISEASE | |
| DK167209B1 (en) | SYNERGISTIC ACTIVE PREPARATION FOR HYPERTENSION TREATMENT | |
| DK0866711T3 (en) | Use of 6-methyl-5-oxo-3-thiomorpholinylcarbonyl-L-histidyl-L-prolinamide for the preparation of a pharmaceutical composition for the prevention of sleep apnea | |
| JP2006505582A5 (en) | ||
| EP1113015A4 (en) | Optically active 3-((2-piperazinyl-phenyl)methyl)-1-(4-(trifluoromethyl)-phenyl)-2-pyrrolidinone compounds as 5-HT1D receptor selective antagonists | |
| DE60011637D1 (en) | DIOXOLAN NUCLEOSIDE ANALOGS FOR THE TREATMENT AND PREVENTION OF VIRAL INFECTIONS | |
| BRPI0411350A (en) | heteroaryl substituted imidazole derivatives as glutamate receptor antagonists |